{
  "generated": "2025-10-27T01:50:36.318281+00:00",
  "policy_fingerprint": "0xbe3a798944b1c64b",
  "source_evidence": "entries/immune/beta-glucan-imm-beta-gluc/immune_health/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "IMM-BETA-GLUC-01",
      "year": 2015,
      "design": "randomized controlled trial",
      "journal": "immune_health-journal-01",
      "outcome": "immune_readiness",
      "population": "Adults with immune readiness concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/imm-beta-gluc-01",
      "url": "https://doi.org/10.1234/imm-beta-gluc-01",
      "citation": "IMM-BETA-GLUC-01 (2015); Journal: immune_health-journal-01; Design: randomized controlled trial; Population: Adults with immune readiness concerns; Outcome: immune_readiness; DOI: 10.1234/imm-beta-gluc-01; Adverse Events: None reported."
    },
    {
      "study_id": "IMM-BETA-GLUC-02",
      "year": 2020,
      "design": "randomized controlled trial",
      "journal": "immune_health-journal-02",
      "outcome": "immune_readiness",
      "population": "Adults with immune readiness concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/imm-beta-gluc-02",
      "url": "https://doi.org/10.1234/imm-beta-gluc-02",
      "citation": "IMM-BETA-GLUC-02 (2020); Journal: immune_health-journal-02; Design: randomized controlled trial; Population: Adults with immune readiness concerns; Outcome: immune_readiness; DOI: 10.1234/imm-beta-gluc-02; Adverse Events: None reported."
    },
    {
      "study_id": "IMM-BETA-GLUC-03",
      "year": 2011,
      "design": "randomized controlled trial",
      "journal": "immune_health-journal-03",
      "outcome": "immune_readiness",
      "population": "Adults with immune readiness concerns",
      "adverse_events": "Transient headache",
      "doi": "10.1234/imm-beta-gluc-03",
      "url": "https://doi.org/10.1234/imm-beta-gluc-03",
      "citation": "IMM-BETA-GLUC-03 (2011); Journal: immune_health-journal-03; Design: randomized controlled trial; Population: Adults with immune readiness concerns; Outcome: immune_readiness; DOI: 10.1234/imm-beta-gluc-03; Adverse Events: Transient headache."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/imm-beta-gluc-01",
      "study_ids": [
        "IMM-BETA-GLUC-01"
      ],
      "primary_study_id": "IMM-BETA-GLUC-01",
      "url": "https://doi.org/10.1234/imm-beta-gluc-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/imm-beta-gluc-02",
      "study_ids": [
        "IMM-BETA-GLUC-02"
      ],
      "primary_study_id": "IMM-BETA-GLUC-02",
      "url": "https://doi.org/10.1234/imm-beta-gluc-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/imm-beta-gluc-03",
      "study_ids": [
        "IMM-BETA-GLUC-03"
      ],
      "primary_study_id": "IMM-BETA-GLUC-03",
      "url": "https://doi.org/10.1234/imm-beta-gluc-03"
    }
  ],
  "manifest_hash": "sha256:31661cd31358728706245f0b65fa0510c4741663c79e0ff4679e9e81b2abe0b8"
}
